Description

Orphenadrine Citrate USP

Orphenadrine Citrate USP is a high-purity, centrally acting muscle relaxant and anticholinergic agent used in pharmaceutical formulations for the treatment of acute musculoskeletal pain, muscle spasms, and related neurologic disorders. As a derivative of diphenhydramine, it exerts both antimuscarinic and NMDA-receptor antagonist properties, making it effective in neuromuscular pain syndromes and adjunctive analgesia.

• USP-compliant skeletal muscle relaxant and anticholinergic agent
• Used in oral tablets and injectable solutions for musculoskeletal pain management
• Provides relief from acute muscle spasms, tension headaches, and nerve-associated pain
• Suitable for combination therapy with NSAIDs or analgesics
• Manufactured under Good Manufacturing Practice (GMP) certified conditions
• Supplied with full regulatory documentation including Certificate of Analysis (CoA), Drug Master File (DMF), and supporting technical data

Orphenadrine Citrate is chemically designated as (±)-N,N-dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine citrate monohydrate. It appears as a white or off-white crystalline powder, freely soluble in water and alcohol, and is often formulated as extended-release or immediate-release oral tablets.

In pharmaceutical applications, Orphenadrine Citrate USP is used in:

• Oral formulations for relief of acute, painful musculoskeletal conditions
• Injectable preparations for hospital use in spasm-related injuries or disorders
• Combination tablets containing aspirin or caffeine for tension-type headaches
• Adjunctive therapy in degenerative or inflammatory joint disease
• Neurologic pain protocols where central anticholinergic activity is beneficial

Orphenadrine exerts antispasmodic effects through central inhibition of motor pathways in the brainstem and spinal cord. Its mild euphoric and analgesic effects can also contribute to symptom relief in certain chronic pain states.

CarboMer supplies Orphenadrine Citrate USP with validated control over assay, enantiomeric purity, related substances, residual solvents, and microbial contamination. Each batch complies with United States Pharmacopeia (USP) specifications and is suitable for use in regulated human pharmaceutical products.

Material is packaged in moisture-resistant, light-protective, tamper-evident containers. Available in R&D, pilot, and commercial volumes. Minimum order quantities (MOQ), lead times, and documentation including CoA, SDS, and DMF access are available upon request.

Each batch is tested for identity (IR, HPLC), assay (anhydrous basis), pH, water content, citrate confirmation, residual solvents, and microbial limits. Certificates of Analysis (CoA), Safety Data Sheets (SDS), and full traceability documentation accompany every shipment.

As with all CarboMer central-acting APIs, Orphenadrine Citrate USP is supported by regulatory strategy, formulation development, and dependable global logistics to ensure your pharmaceutical products are safe, effective, and market-ready.